Indeed, lipid metabolism has been gaining interest in the neuroblastoma field lately as it offers novel and promising therapeutic strategies.[55] For instance, inhibiting β‐oxidation with Etomoxir diminished in vivo tumor growth in MYCN‐amplified neuroblastoma cells,[56] while small‐molecule inhibitors of de novo fatty acid synthesis reduced neuroblastoma growth both in vitro and in vivo.[57] Of note, an ongoing clinical trial (ClinicalTrials.gov identifier: NCT04565717) is testing the use of HSD17B13 inhibitors to treat liver steatosis. The gene discussed is MYCN; the disease is neuroblastoma.